David H Moore

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi request reprint The role of radical hysterectomy and neoadjuvant chemotherapy in carcinoma of the cervix
    David H Moore
    Department of Gynecologic Oncology, Indiana University School of Medicine, 535 Barnhill Drive RT433, Indianapolis, IN 46202 5274, USA
    Curr Oncol Rep 4:145-51. 2002
  2. ncbi request reprint Combined chemotherapy and radiation therapy for cervical cancer
    David H Moore
    Department of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis, IN 46202 5274, USA
    J Natl Compr Canc Netw 2:631-5. 2004
  3. ncbi request reprint Neoadjuvant chemotherapy for cervical cancer
    David H Moore
    Indiana University School of Medicine, 535 Barnhill Drive RT433, Indianapolis, IN 46202 5274, USA
    Expert Opin Pharmacother 4:859-67. 2003
  4. ncbi request reprint Cervical cancer
    David H Moore
    Department of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:1152-61. 2006
  5. ncbi request reprint An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study
    David H Moore
    Department of Obstetrics Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202 5274, USA
    Gynecol Oncol 94:368-74. 2004
  6. doi request reprint A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study
    David H Moore
    Gynecologic Oncology of Indiana, Indianapolis, IN 46237, USA
    Gynecol Oncol 124:529-33. 2012
  7. ncbi request reprint Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    David H Moore
    Indiana University School of Medicine, 3535 Barnhill Dr, RT433, Indianapolis, IN 46202 5274 e mail
    J Clin Oncol 22:3113-9. 2004
  8. ncbi request reprint Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Mitchell Morris
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 22:3340-4. 2004
  9. doi request reprint Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study
    David H Moore
    Gynecologic Oncology of Indiana, 5255 East Stop 11 Road, Suite 310, Indianapolis, IN 46237, USA
    Gynecol Oncol 116:44-9. 2010
  10. ncbi request reprint Treatment of stage IB2 (bulky) cervical carcinoma
    David H Moore
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer Treat Rev 29:401-6. 2003

Detail Information

Publications23

  1. ncbi request reprint The role of radical hysterectomy and neoadjuvant chemotherapy in carcinoma of the cervix
    David H Moore
    Department of Gynecologic Oncology, Indiana University School of Medicine, 535 Barnhill Drive RT433, Indianapolis, IN 46202 5274, USA
    Curr Oncol Rep 4:145-51. 2002
    ..There are still too few comparative studies and phase III trials to assess the effectiveness of neoadjuvant chemotherapy and radical surgery relative to standard treatments...
  2. ncbi request reprint Combined chemotherapy and radiation therapy for cervical cancer
    David H Moore
    Department of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis, IN 46202 5274, USA
    J Natl Compr Canc Netw 2:631-5. 2004
    ..Therapies specific to tumor hypoxia (tirapazamine) or strategies to maintain higher nadir hemoglobin levels during treatment (aggressive transfusion policies; erythropoietin) should also be studied...
  3. ncbi request reprint Neoadjuvant chemotherapy for cervical cancer
    David H Moore
    Indiana University School of Medicine, 535 Barnhill Drive RT433, Indianapolis, IN 46202 5274, USA
    Expert Opin Pharmacother 4:859-67. 2003
    ..Although there are too few randomised controlled studies to determine the effectiveness of NACT approaches, relative to standard treatments...
  4. ncbi request reprint Cervical cancer
    David H Moore
    Department of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:1152-61. 2006
    ..Whenever possible, these discussions will unfold through an overview of pertinent clinical trials and current controversies...
  5. ncbi request reprint An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study
    David H Moore
    Department of Obstetrics Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202 5274, USA
    Gynecol Oncol 94:368-74. 2004
    ..To assess the frequency with which patients with epithelial ovarian cancer are enrolled in prospective Gynecologic Oncology Group (GOG) treatment studies and to assess whether enrollment is influenced by patient age or other factors...
  6. doi request reprint A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study
    David H Moore
    Gynecologic Oncology of Indiana, Indianapolis, IN 46237, USA
    Gynecol Oncol 124:529-33. 2012
    ..To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma...
  7. ncbi request reprint Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    David H Moore
    Indiana University School of Medicine, 3535 Barnhill Dr, RT433, Indianapolis, IN 46202 5274 e mail
    J Clin Oncol 22:3113-9. 2004
    ..Tumor measurements and quality-of-life (QOL) assessments were obtained before each treatment cycle...
  8. ncbi request reprint Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Mitchell Morris
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 22:3340-4. 2004
    ..To evaluate the efficacy and toxicity of intravenous cisplatin and vinorelbine as combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the cervix...
  9. doi request reprint Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study
    David H Moore
    Gynecologic Oncology of Indiana, 5255 East Stop 11 Road, Suite 310, Indianapolis, IN 46237, USA
    Gynecol Oncol 116:44-9. 2010
    ..This study was undertaken to identify the prognostic factors and develop a model predictive of (non-) response to chemotherapy...
  10. ncbi request reprint Treatment of stage IB2 (bulky) cervical carcinoma
    David H Moore
    Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer Treat Rev 29:401-6. 2003
    ..These emerging treatments should be scrutinized in prospective controlled trials...
  11. ncbi request reprint Chemotherapy for advanced, recurrent, and metastatic cervical cancer
    David H Moore
    Gynecologic Oncology of Indiana, 5255 East Stop 11 Road, Suite 310, Indianapolis, IN 46237, USA
    J Natl Compr Canc Netw 6:53-7. 2008
    ..Furthermore, if the predictive model is upheld, then patients with high risk factors for treatment failure may be directed to chemotherapy regimens that do not include cisplatin or to investigational trials...
  12. ncbi request reprint Chemotherapy for recurrent cervical carcinoma
    David H Moore
    Gynecologic Oncology of Indiana, Indianapolis, Indiana 46237, USA
    Curr Opin Oncol 18:516-9. 2006
    ..The purpose of this review is to highlight the evolution of phase III trials leading to current treatment standards...
  13. ncbi request reprint Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study
    Achilles J Fakiris
    Indiana University School of Medicine, 535 Barnhill Drive, RT 041 Indianapolis, IN 46202 5289, USA
    Gynecol Oncol 96:818-23. 2005
    ....
  14. ncbi request reprint Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group
    David H Moore
    Department of Obstetrics Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 21:4207-13. 2003
    ..The purpose of this study was to determine whether amifostine (WR-2721) prevents or ameliorates clinically significant (grade 2 to 4) neurotoxicity associated with cisplatin and 3-hour paclitaxel chemotherapy. Materials and..
  15. doi request reprint Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?
    David H Moore
    Gynecologic Oncology of Indiana, Indianapolis, IN 46237, USA
    Gynecol Oncol 113:379-83. 2009
    ..Nonetheless, patients with locally advanced vulva cancer have derived considerable benefit from chemoradiation studies in other related tumor sites, and will continue to do so in the future...
  16. ncbi request reprint Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance
    Sarah Freitas
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 9:4689-94. 2003
    ..The purpose of this study is to determine whether APE/ref-1 expression differs with ovarian cancer progression and metastasis and in platinum-resistant disease...
  17. ncbi request reprint Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study
    Rachelle Lanciano
    Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    J Clin Oncol 23:8289-95. 2005
    ..This trial was designed to compare the outcome of protracted venous infusion (PVI) fluorouracil (FU) with standard weekly cisplatin and concurrent radiation therapy (RT)...
  18. ncbi request reprint Secondary surgical cytoreduction for advanced ovarian carcinoma
    Peter G Rose
    Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center, Cleveland, USA
    N Engl J Med 351:2489-97. 2004
    ....
  19. pmc Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study
    Agustin A Garcia
    Premiere Oncology, 2020 Santa Monica Blvd Santa Monica, CA 90404, USA
    Gynecol Oncol 104:572-9. 2007
    ..To evaluate the anti-tumor activity and adverse events of capecitabine in advanced, persistent or recurrent squamous cell carcinoma of the cervix, and to explore biomarkers with the potential to predict capecitabine response and toxicity...
  20. ncbi request reprint Surgical staging and cervical cancer: after 30 years, have we reached a conclusion?
    David H Moore
    Cancer 112:1874-6. 2008
  21. ncbi request reprint Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study
    Richard P McQuellon
    Psychosocial Oncology, Comprehensive Cancer Center of Wake Forest University, Department of Internal Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1082, USA
    Gynecol Oncol 101:296-304. 2006
    ..Our purpose was to assess the impact of cisplatin (C) versus cisplatin plus paclitaxel (CP) on overall QOL and pain in cervical cancer patients...
  22. ncbi request reprint A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University, Division of Gynecologic Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 88:130-5. 2003
    ..The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients...
  23. ncbi request reprint Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study
    Steven E Waggoner
    Department of Reproductive Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 103:853-8. 2006
    ..To determine if smoking, a known risk factor for a number of cancers including cervical cancer, is associated with poor prognosis in patients with locally advanced cervical carcinoma treated with chemoradiation...